Stephen Liu

No bio available.

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Gilead
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Guardant Health
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Jazz Pharmaceuticals,
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Merck
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Merus
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Mirati
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Novartis
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Regeneron
    Date added:
    08/14/2023
    Date updated:
    08/14/2023
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Sanofi
    Date added:
    08/14/2023
    Date updated:
    08/14/2023

Pages

Return to 2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond